SCHEMBL589076

SCHEMBL589076

C1=CCC2(C1)CC=CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565060 0.80
SCHEMBL16821283 0.71
SCHEMBL11775307 0.71
SCHEMBL1855995 0.69
SCHEMBL584838 0.67 TSHR (0.37)
SCHEMBL7088547 0.67
SCHEMBL2326 0.45
SCHEMBL34570 0.45
SCHEMBL25407819 0.41
SCHEMBL17688346 0.41

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11752713-B2 Polymer composition and methods using said polymer composition to manufacture ophthalmic lens ESSILOR INTERNATIONAL (FR) 2023-09-12 US disclosed
US-20210072425-A1 Polymer Composition and Methods Using Said Polymer Composition to Manufacture Ophthalmic Lens ESSILOR INTERNATIONAL (FR) 2021-03-11 US disclosed
EP-2488028-B1 SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF MERCK SHARP & DOHME (US) 2020-08-19 EP disclosed
EP-3084484-B1 POLYMER COMPOSITION AND METHODS USING SAID POLYMER COMPOSITION TO MANUFACTURE OPHTHALMIC LENS ESSILOR INT (FR) 2018-03-21 EP disclosed
US-20170031059-A1 Polymer Composition and Methods Using Said Polymer Composition to Manufacture Ophthalmic Lens ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) 2017-02-02 US disclosed
EP-3084484-A1 POLYMER COMPOSITION AND METHODS USING SAID POLYMER COMPOSITION TO MANUFACTURE OPHTHALMIC LENS Essilor International (Compagnie Générale D'Optique) (FR) 2016-10-26 EP disclosed
EP-2880030-A1 BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF Sunshine Lake Pharma Co., Ltd. (CN) 2015-06-10 EP disclosed
US-8859776-B2 Substituted piperidines that increase p53 activity and the uses thereof MERCK SHARP & DOHME CORP. (US) 2014-10-14 US disclosed
WO-2014019344-A1 BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2014-02-06 WO disclosed
US-8591943-B2 Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors MERCK SHARP & DOHME CORP. (US) 2013-11-26 US disclosed
WO-2009097233-A1 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2009-08-06 WO disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
EP-2035416-A1 SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF SCHERING CORPORATION (US) 2009-03-18 EP disclosed
WO-2009017701-A2 ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT SCHERING CORPORATION (US) 2009-02-05 WO disclosed
WO-2009008913-A2 P1-NONEPIMERIZABLE KETOAMIDE INHIBITORS OF HCV NS3 PROTEASE SCHERING CORPORATION (US) 2009-01-15 WO disclosed
WO-2008156614-A2 IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS SCHERING CORPORATION (US) 2008-12-24 WO disclosed
WO-2008118332-A2 HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE SCHERING CORPORATION (US) 2008-10-02 WO disclosed
WO-2008115381-A1 PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS SCHERING CORPORATION (US) 2008-09-25 WO disclosed
WO-2008005268-A1 SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF SCHERING CORPORATION (US) 2008-01-10 WO disclosed
US-20080004287-A1 Substituted Piperidines that Increase P53 Activity and the Uses Thereof SCHERING CORPORATION 2008-01-03 US disclosed